Publications by authors named "Marcus Butler"

Claim this Profile
I
Incidence and Management of Adverse Events Associated with Tebentafusp Treatment in Metastatic Uveal Melanoma: Pooled Safety Analysis of 410 Patients.
Takami Sato, Marcus O Butler, Sophie Piperno-Neumann, Jessica C Hassel, Paul Nathan

Clin Cancer Res· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Delineation and monitoring of the T cell repertoire of adoptive cell transfer product during the treatment of advanced melanoma.
Cameron Kerr, Shirin Soleimani, David T Mulder, Arash Nabbi, Diana Gray, Marcus O Butler

Genome Med· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Elucidating divergent biology in uterine carcinosarcoma.
Vikas Garg, Stephenie D Prokopec, Simone C Stone, Sara Pakbaz, Min Li Chen, Marcus O Butler

Transl Oncol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Response to Immune Checkpoint Blockade is Enhanced in the Presence of Hematopoietic TET2 Inactivation.
Vincent Rondeau, Suraj Bansal, Marco M Buttigieg, Andy G X Zeng, Darryl Y Chan, Marcus O Butler

Cancer Res· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Parsing the Patterns: Not All Drug-Induced Interstitial Lung Diseases Are Alike. Understanding Drug-Induced Interstitial Lung Disease in the Era of Targeted Cancer Therapy.
Niamh Boyle, Marcus W Butler

Respirology· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nivolumab for Resected Stage III or IV Melanoma at 9 Years.
Paolo A Ascierto, Michele Del Vecchio, Barbara Merelli, Helen Gogas, Ana M Arance, Marcus O Butler

N Engl J Med· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neurodevelopmental hijacking of oligodendrocyte lineage programs drives glioblastoma infiltration.
Yiyan Wu, Benson Z Wu, Yosef Ellenbogen, Joan B Y Kant, Pengcheng Yu, Marcus O Butler

Dev Cell· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
T cell receptor repertoire in cell-free DNA as a proxy for tumor infiltrates in patients treated with pembrolizumab.
Shirin Soleimani, Xuan Li, Ben X Wang, Stephanie Pedersen, Jeffrey P Bruce, Marcus O Butler

Cell Rep· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Interleukin-12 anchored drug conjugate (tolododekin alfa) in patients with advanced solid tumors: first-in-human Phase 1 trial.
Jong Chul Park, Brendan Curti, Marcus Butler, Eric Wehrenberg-Klee, Joseph Elassal

Nat Commun· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Erratum: Randomized, Open-Label, Phase III Study of Tilsotolimod in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced Refractory Melanoma (ILLUMINATE-301).
Adi Diab, Paolo A Ascierto, Michele Maio, Reham Abdel-Wahab, Sylvie Negrier, Marcus O Butler

J Clin Oncol· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Longitudinal Genomic Analysis to Fine-tune Targeted Therapy: Results of the Phase II LOGIC 2 Trial in Patients with BRAFV600-Mutant Metastatic Melanoma.
Reinhard Dummer, Shahneen Sandhu, Wilson H Miller, Marcus O Butler, Matthew H Taylor

Clin Cancer Res· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized, Open-Label, Phase III Study of Tilsotolimod in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced Refractory Melanoma (ILLUMINATE-301).
Adi Diab, Paolo A Ascierto, Michele Maio, Reham Abdel-Wahab, Sylvie Negrier, Marcus O Butler

J Clin Oncol· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 1 study of IMCnyeso, a T cell receptor bispecific ImmTAC targeting NY-ESO-1-expressing malignancies.
Juanita S Lopez, Mohammed Milhem, Marcus O Butler, Fiona Thistlethwaite, Brian A Van Tine

Cell Rep Med· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evolution of the tumor immune landscape during treatment with tebentafusp, a T cell receptor-CD3 bispecific.
Joseph J Sacco, Peter Kirk, Emma Leach, Alexander N Shoushtari, Richard D Carvajal, Marcus O Butler

Cell Rep Med· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immune Checkpoint Inhibitor-Induced Pancreatic Injury (ICI-PI) in Adult Cancer Patients: A Systematic Review and Meta-Analysis.
Cha Len Lee, Israt Jahan Riya, Ifrat Jahan Piya, Thiago Pimentel Muniz, Marcus Otho Butler

Cancers (Basel)· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Final, 10-Year Outcomes with Nivolumab plus Ipilimumab in Advanced Melanoma.
Jedd D Wolchok, Vanna Chiarion-Sileni, Piotr Rutkowski, C Lance Cowey, Dirk Schadendorf, Marcus O Butler

N Engl J Med· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment sequence with tebentafusp and immune checkpoint inhibitors in patients with metastatic uveal melanoma and metastatic GNA11/GNAQ mutant melanocytic tumors.
Florentia Dimitriou, Marlana M Orloff, Erica C Koch Hein, Phil F Cheng, Isaac F Hughes, Marcus O Butler

Eur J Cancer· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Female Oncofertility and Immune Checkpoint Blockade in Melanoma: Where Are We Today?
Cha Len Lee, Erika Martinez, Diego Malon Gimenez, Thiago Pimentel Muniz, Marcus Otho Butler

Cancers (Basel)· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outcomes With Postrecurrence Systemic Therapy Following Adjuvant Checkpoint Inhibitor Treatment for Resected Melanoma in CheckMate 238.
Jeffrey Weber, Michele Del Vecchio, Mario Mandalá, Helen Gogas, Ana M Arance, Marcus O Butler

J Clin Oncol· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pembrolizumab for the First-Line Treatment of Recurrent Locally Advanced or Metastatic Merkel Cell Carcinoma: Results from the Single-Arm, Open-Label, Phase III KEYNOTE-913 Study.
Laurent Mortier, Lisa Villabona, Ben Lawrence, Ana Arance, Marcus O Butler

Am J Clin Dermatol· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inhibition of Notch enhances efficacy of immune checkpoint blockade in triple-negative breast cancer.
Qiang Shen, Kiichi Murakami, Valentin Sotov, Marcus Butler, Pamela S Ohashi

Sci Adv· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Caspase-1-dependent spatiality in triple-negative breast cancer and response to immunotherapy.
Weiyue Zheng, Wanda Marini, Kiichi Murakami, Valentin Sotov, Marcus Butler

Nat Commun· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of Active Chronic Cigarette-Smoke Exposure on Circulating Fibrocytes.
Faheem Khan, Eoin P Judge, Jeeban P Das, Daniel White, Carolyn Ingram, Marcus W Butler

Lung· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term survival follow-up for tebentafusp in previously treated metastatic uveal melanoma.
Joseph J Sacco, Richard D Carvajal, Marcus O Butler, Alexander N Shoushtari, Jessica C Hassel

J Immunother Cancer· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identifying MAGE-A4-positive tumors for TCR T cell therapies in HLA-A∗02-eligible patients.
Tianjiao Wang, Jean-Marc Navenot, Stavros Rafail, Cynthia Kurtis, Mark Carroll, Marcus O Butler

Mol Ther Methods Clin Dev· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis